Pfizer Inlyta’s Toxicity Data Help Clinch Unanimous ODAC Support
This article was originally published in The Pink Sheet Daily
Axitinib as treatment for advanced renal cell carcinoma has a different toxicity profile from Bayer HealthCare's Nexavar (sorafenib), which member of the Oncologic Drugs Advisory Committee found important, even as FDA urged the panel not to focus on compartive safety and effecacy.
You may also be interested in...
Pfizer's Inlyta (axitinib), proposed to treat patients with advanced renal cell carcinoma, seems to work best with patients who have undergone cytokine treatment.
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.